Effects of long-term treatment with warfarin on fibrinogen, FPA, TAT, and D-dimer in patients with coronary artery disease.
Sixty-four patients undergoing aorto-coronary bypass surgery were randomized to receive antithrombotic treatment with acetylsalicylic acid (ASA), 300 mg/d (n = 30) or warfarin, INR = 2.5 - 4.2 (n = 34). The levels of fibrinogen, thrombin-antithrombin III complexes (TAT), fibrinopeptide A (FPA) and D-dimer were assessed before surgery and 9 months postoperatively. In the warfarin treated group the fibrinogen levels were increased after 9 months, while the levels of TAT, FPA and D-dimer were decreased. In the ASA group TAT levels were increased at 9 months, whereas no significant changes in fibrinogen, FPA or D-dimer from baseline were noted. Thus, a reduced activation of the coagulation system has been demonstrated during long-term treatment with warfarin in patients with coronary artery disease.
Eritsland
J
J
Dept. of Cardiology, Ullevål Hospital, Oslo, Norway.
Seljeflot
I
I
Arnesen
H
H
Smith
P
P
Westvik
A B
AB
D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000378:metabolism*; D003131:Combined Modality Therapy; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D005340:Fibrinogen / Q000378:metabolism*; D005344:Fibrinopeptide A / Q000378:metabolism*; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000378:metabolism*; D013997:Time Factors; D014859:Warfarin / Q000008:administration & dosage*
D005338:Fibrin Fibrinogen Degradation Products; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D005344:Fibrinopeptide A; D014859:Warfarin; D000990:Antithrombin III; D005340:Fibrinogen; D010447:Peptide Hydrolases